Related Experiment Video
Updated: Jul 18, 2026

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
[Cryptogenic organizing pneumonia: CT features and the effect of glucocorticoids]
Xiao-hua Zhu1, Tian-nü Li, Zheng-qian You
1Department of Radiology, Shanghai Pneumology Hospital, Shanghai 200433, China.
Objective:
To study the CT manifestations of cryptogenic organizing pneumonia (COP) after glucocorticoid treatment.
Methods:
The diagnosis of COP was made based on clinical and radiological features and confirmed by lung biopsy and pathological examination in 21 cases from 2001 to 2005. CT follow-up was carried out 5 - 75 days following therapy. The follow-up lasted 3 - 43 months. All data were analyzed and relevant literatures were reviewed.
Results:
There were 2 male an 19 female patients with ages of 39 - 74 years. CT scans revealed multiple patchy shadows or patchy air-space consolidations, often by a predominantly subpleural and/or basal distribution. Ground-glass opacities and bronchiectasis were common findings. Migratory lesions were found in some patients. Glucocorticoid treatment resulted in significant improvement in most cases. Cure was achieved in 4 cases, significant improvement in 16, and failure in 1 case. Recurrence was found in 2 cases.
Conclusions:
The diagnosis of COP requires combination of clinical, CT and pathological manifestations. The effect of glucocorticoid therapy can be evaluated by repeated CT scanning.
Related Concept Videos
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Cryptococcal Meningitis
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
COPD: Management Using Bronchodilators and Corticosteroids